The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
June 24, 2024
View Complete Issue         Table of Contents 2019 
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
June 24, 2024 (Issue: 1705)
The FDA has approved tebentafusp-tebn (Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
Article code: 1705f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.